Menarini Türkiye'den haberleri görmek için sosyal medya adreslerimize tıklayınız.
PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group (“Menarini”) today announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.
NEWTON, Mass. and FLORENCE, Italy, – July 21, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted Marketing Authorisation for NEXPOVIO® (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor
Merkez: Maslak Ofis Binası (MOB) Maslak Mahallesi,
Sümer Sokak, No: 4, Kat: 7-8 Sarıyer 34485 İstanbul
Üretim Tesisi: Davutpaşa Caddesi, No: 12, Topkapı 34010 İstanbul
T: +90 212 467 11 11 / F: +90 212 467 12 12
Menarini Türkiye Maltepe MahallesiDavutpaşa Cd. No:1234010Zeytinburnu/İstanbul, Turkey